Boots’ sunscreen lotion fails sun protection test, says Which? Two sunscreens, including one manufactured by Boots, have failed sun protection tests, according to research conducted by the UK consumer watchdog Which? …
Burns: assessment and treatment Quick action is required with burns to minimise tissue damage and prevent infection.…
Unnecessary visits to A&E will continue to occurI wish to comment on Adam Pattison Rathbone’s blog ‘Could pharmacists be part of the A&E problem?’ ( The Pharmaceutical Journal 2015;294:385). I would like to share a recent experience of mine that illustrates how the pressures on out-of-hour GP services and a…
Tildrakizumab shows promise as psoriasis treatment Merck reports in a phase I trial that its new monoclonal antibody, tildrakizumab, reduces psoriasis symptoms.…
First-in-class oral drug approved for psoriasis conditions in Europe The European Commission has authorised apremilast (Celgene’s Otezla), a first-in-class oral drug for the treatment of chronic plaque psoriasis and psoriatic arthritis in patients who have failed first-line systemic therapies.…
Top 10 learning articles of 2014 from The Pharmaceutical Journal Our response to the Ebola outbreak is a sign of how our learning content is changing to meet your needs.…
Illustrating disease in the 19th century ‘The Sick Rose or; Disease and the art of medical illustration’, by Richard Barnett.…
Immune checkpoint inhibitors bring new hope to cancer patients PD-1 and PD-L1 inhibitors induce a higher response rate across a wider range of tumours than other immunotherapies.…
Diabetic wounds heal faster with deferoxamine patch Researchers have developed a transdermal patch that delivers the small molecule deferoxamine to accelerate wound healing in diabetes.…
First drug for rare sun disease recommended for approval in Europe The European Medicines Agency recommends that Scenesse (afamelanotide) should be approved for the prevention of severe sunburn in patients with erythropoietic protoporphyria.…
